Sofinnova closes €650m healthcare fund for early-stage ventures

Fund Overview - Sofinnova Partners has closed its latest fund, Sofinnova Capital XI, at €650 million ($750 million), exceeding its initial target [1] - The fund will focus on early-stage healthcare companies in the US and Europe, particularly in medical technology and biopharmaceuticals [1] Investment Strategy - The fund will leverage the expertise of partners with backgrounds in medical, business, and scientific fields [2][6] - It will participate in both follow-on and initial funding rounds, maintaining a focus on early-stage biotech and medtech ventures [2] Investor Commitment - The fund has secured commitments from a global network of institutional investors, including foundations, corporates, family offices, insurance companies, sovereign wealth funds, and pharmaceutical companies [3] - Investors are from Europe, Asia, North America, and the Middle East, with a mix of returning and new limited partners, indicating strong interest in Sofinnova's strategy [3] Management Insights - Antoine Papiernik, managing partner and chairman, emphasized that this fundraising is a pivotal moment for Sofinnova, allowing for increased investment in early-stage opportunities [4] - The firm aims to support visionary entrepreneurs and advance breakthroughs in science and medicine, reflecting confidence in their investment model [5] Current Activities - Sofinnova Capital XI is actively deploying capital and has already invested in several portfolio companies [5]